Luc Gagnon

Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays

Kevin R. Bewley, Naomi S. Coombes, Luc Gagnon et al. · Nature Protocols · 2021 · 321 citations · Full text

Life Sciences, Immunology, Infectious Diseases +14

Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial

Scott A. Halperin, Lingyun Ye, Donna MacKinnon‐Cameron et al. · The Lancet · 2021 · 237 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial

Punnee Pitisuttithum, Viravarn Luvira, Saranath Lawpoolsri et al. · EClinicalMedicine · 2022 · 55 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models

Pauline Maisonnasse, Yoann Aldon, Aurélien Marc et al. · Nature Communications · 2021 · 54 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models

Pauline Maisonnasse, Yoann Aldon, Aurélien Marc et al. · Research Square · 2021 · 20 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17